Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$3.94
-7.1%
$2.90
$1.89
$4.46
$1.27B0.623.52 million shs6.77 million shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$3.24
-6.3%
$3.31
$1.53
$4.05
$330.99M0.7364,491 shs6,516 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$11.48
-3.9%
$9.21
$5.90
$28.18
$1.24B2.213.04 million shs3.45 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$30.56
-3.1%
$25.26
$16.16
$31.80
$1.28B0.75222,250 shs295,791 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-7.08%+1.29%+23.13%+64.85%+23.13%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-6.33%-6.33%-4.96%-2.08%+21.39%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-3.93%+3.24%+38.15%+67.35%-55.86%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-3.11%+1.46%+27.71%+81.58%+73.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.2789 of 5 stars
3.51.00.00.02.73.30.0
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
3.162 of 5 stars
3.45.00.00.02.41.70.6
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.3114 of 5 stars
4.31.00.04.71.42.50.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.9968 of 5 stars
0.94.02.51.13.23.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
3.00
Buy$8.75122.08% Upside
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40220.89% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.65
Moderate Buy$33.37190.67% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-20.16% Downside

Current Analyst Ratings Breakdown

Latest IVA, PAHC, ABCL, and NTLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
6/3/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $54.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00 ➝ $7.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M40.78N/AN/A$3.58 per share1.10
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$9.95M31.16N/AN/A($1.21) per share-2.68
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$45.57M26.10N/AN/A$8.56 per share1.34
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.22$2.05 per share14.92$6.34 per share4.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7839.1814.550.532.68%30.51%6.89%8/27/2025 (Estimated)

Latest IVA, PAHC, ABCL, and NTLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17N/AN/AN/A$7.55 millionN/A
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.57%N/A61.54%N/A

Latest IVA, PAHC, ABCL, and NTLA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
10.15
10.15
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
0.92
0.92
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
4.90
4.90
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.18 millionOptionable
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
10095.66 million65.05 millionNot Optionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million100.37 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable

Recent News About These Companies

PAHC Phibro Animal Health Corporation - Seeking Alpha
Best Growth Stocks to Buy for July 10th
Best Growth Stocks to Buy for July 8th
Overlooked Stock: PAHC Taps 4-Year High

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$3.94 -0.30 (-7.08%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$4.06 +0.12 (+3.05%)
As of 07:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.24 -0.22 (-6.33%)
Closing price 07/15/2025 03:59 PM Eastern
Extended Trading
$3.38 +0.14 (+4.41%)
As of 07/15/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$11.48 -0.47 (-3.93%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$11.58 +0.10 (+0.87%)
As of 07:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$30.56 -0.98 (-3.11%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$30.57 +0.01 (+0.03%)
As of 07/15/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.